Key terms
About SYRS
Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425, SY-2101, and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SYRS news
Apr 12
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Apr 11
11:20am ET
Biotech Alert: Searches spiking for these stocks today
Apr 03
7:06am ET
Syros Pharmaceuticals (SYRS) Receives a Buy from Piper Sandler
Apr 01
6:18am ET
Buy Rating Affirmed for Syros Pharmaceuticals Amid Promising Clinical Trials and Strategic Study Designs
Mar 27
7:32am ET
Syros Pharmaceuticals reports Q4 EPS ($2.18), consensus ($1.14)
Mar 25
12:05pm ET
Buy Rating Affirmed for Syros Pharmaceuticals Amidst Promising Clinical Trial Developments
Mar 25
7:07am ET
Syros Pharmaceuticals completes enrollment of SELECT-MDS-1 trial
Jan 25
11:38am ET
Biotech Alert: Searches spiking for these stocks today
Jan 25
11:38am ET
Biotech Alert: Searches spiking for these stocks today
Jan 24
11:08am ET
Biotech Alert: Searches spiking for these stocks today
Jan 22
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Jan 19
6:28am ET
5 Top Penny Stocks to Buy Now, According to Analysts – January 2024
No recent press releases are available for SYRS
SYRS Financials
Key terms
Ad Feedback
SYRS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SYRS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range